NeoGenomics (NEO) Completes Acquisition of Pathline

NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it has completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.

With the acquisition, NeoGenomics strengthens its commercial presence in the Northeast U.S. and broadens access to its comprehensive oncology test menu, expands its service capabilities, and accelerates growth in molecular and hematology-oncology testing.

You May Also Be Interested In

• Qualcomm to launch data center CPU in mid-2028 - Data Center Chief
• Google Delays Gemini 3.5 Pro Launch To July - Insider
• Corning (GLW) Declares $0.28 Quarterly Dividend; 0.5% Yield